# Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia

> clinical trial · VERIFIED · 2026-07-30

Status: RECRUITING · Sponsor: Newron Pharmaceuticals SPA · Condition: Treatment-resistant Schizophrenia

- Company: Newron Pharmaceuticals SPA
- Sector: Treatment-resistant Schizophrenia
- Primary source: https://clinicaltrials.gov/study/NCT07184619

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.